Celgene Corp (NASDAQ:CELG)
A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Schnoob
(60.87)
Submitted: 12/17/2006 4:01:46 PM :
Start Price:
$58.75
CELG Score:
+18.91
Its all good. the drugs they have on the market know are selling well and generic wont come to market for at least 2-3 years.
Margins are good and pipeling looks good
Recs
JApple888
(< 20)
Submitted: 12/14/2006 11:35:12 PM :
Start Price:
$57.35
CELG Score:
+21.98
Celgene provides cancer research and drugs which help fight the disease. I believe in this business model given the market need for such drugs.
Recs
iambigred
(51.11)
Submitted: 12/14/2006 8:33:09 PM :
Start Price:
$57.35
CELG Score:
+21.98
biotech chasing the uncontrolled growth that is cancer - and winning. EPS have been increasing for the last four years and this year will exceed 175% - 2007 should also top 100%. a great chart for any investor
Recs
ROVEL41
(59.48)
Submitted: 12/8/2006 2:10:48 AM :
Start Price:
$55.51
CELG Score:
+24.75
will reach $70.00 next year
Recs
scottyhix
(< 20)
Submitted: 12/5/2006 12:15:46 AM :
Start Price:
$58.47
CELG Score:
+17.91
Continual growth in quarterly earnings make this a stock poised for huge gains!
Recs
haveasamy
(< 20)
Submitted: 12/4/2006 10:25:00 PM :
Start Price:
$58.47
CELG Score:
+17.91
Revilmid is a game changing drug. EU approval will more than double the market. Approvals in CLL and NHL as well as the possibility of Rev as a front line treatment could make this a 4B drug in 5 years and this is only one of many new drugs in CELG's pipeline.
Recs
vetnvild
(< 20)
Submitted: 12/3/2006 5:24:06 PM :
Start Price:
$56.75
CELG Score:
+21.44
Barring the unforseen disaster, working on cancer concerns with good management can only lead to profit
Recs
sitrat
(21.67)
Submitted: 12/2/2006 10:41:17 PM :
Start Price:
$56.75
CELG Score:
+21.44
huge profits in their upcoming products as they get approval
Recs
52elgaejp
(< 20)
Submitted: 11/27/2006 9:14:02 AM :
Start Price:
$54.83
CELG Score:
+25.65
One of the fastest growing biotechs with relatively recent approval of Revlimid, which, I believe will be rapidly accepted and will have increasing indications shortly. Analysts have not fully priced in the implications of these increasing indications. Pipeline includes IMID's. Although the trailing 12 month PE is very high, this is PAST HISTORY. Company expected to grow over 100% this year, even by conservative analyst expectations. It has just entered the mid-large cap realm, has recently been added to S&P 500, has raised over one billion dollars in cash (by selling stock from it's treasury at market price to funds that needed stock to comply with ETF, mutual fund requirements as a result of being added to the S&P), to fund future research, also not reflected yet on income statements.
Recs
Recs
grampa9
(< 20)
Submitted: 11/8/2006 6:54:03 PM :
Start Price:
$54.86
CELG Score:
+24.74
They have a series of drugs in their testing pipeline that are unique. revlimid will be joined in about two years by another set of very profitable drugs
Recs
victoder
(64.95)
Submitted: 10/28/2006 12:50:02 PM :
Start Price:
$48.59
CELG Score:
+39.91
Earnings groth
Recs
norfor
(70.09)
Submitted: 10/22/2006 1:01:51 PM :
Start Price:
$45.27
CELG Score:
+49.53
should show good earning,mostly built into price but not all.
Recs
Rob308
(< 20)
Submitted: 10/16/2006 1:53:28 PM :
Start Price:
$45.60
CELG Score:
+48.64
CELG will be $50 by end of the year
Recs
Whoop04
(92.77)
Submitted: 10/13/2006 9:34:41 PM :
Start Price:
$45.90
CELG Score:
+47.40
10/2006
94
Earnings Per Share (EPS) Rating
97
Relative Price Strength (RS) Rating
88
Industry Group Relative Strength (Grp RS) Rating
A-
Sales + Profit Margins + ROE (SMR) Rating
A
Accumulation/ Distribution (Acc/Dis) Rating
B-
Recs
SageoftheNet
(< 20)
Submitted: 10/10/2006 3:33:03 PM :
Start Price:
$45.90
CELG Score:
+46.43
Naysayers love to point to CELG's lofty multiple to sales/earnings on a trailing and even looking forward basis. But even the rosiest '07 and '08 analysts' projections are well short of reality. Revlimid is much bigger than anyone anticipates; it will serve far more patients that currently projected, and as important, for a longer duration per patient. And Revlimid is only the beginning of this Company's healthy pipeline.
Recs
faseoff
(44.79)
Submitted: 9/29/2006 9:17:56 PM :
Start Price:
$43.45
CELG Score:
+53.56
Continues to climb
Recs
3kidsjones
(86.84)
Submitted: 9/29/2006 9:08:37 PM :
Start Price:
$43.45
CELG Score:
+53.56
CELG has an exciting new product in Revlimid, a tremendous pipeline and a savvy management team that is making all the right moves and will continue to grow this outstanding company
Recs
kingheller
(71.39)
Submitted: 9/27/2006 10:59:47 AM :
Start Price:
$42.06
CELG Score:
+58.72
sells at a very high PE but earnings will be increasing at a exponential rate with further FDA approvial of its already approved drug for other cancers
Recs
nepedal
(25.71)
Submitted: 9/21/2006 5:22:45 PM :
Start Price:
$41.10
CELG Score:
+61.78
Revlimid will be a blockbuster and it has incredible margins. New trials in CLL and NHL. Phase III trials for the next IMID. The company is a bit pricey but it has the best pipeline in biotech. Hold this long enough and you will prosper.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 181 - 200 of 207 : « Previous 5 6 7 8 9 10 11 Next »